Adjuvant nivolumab after preoperative chemoradiotherapy and surgery in esophageal cancer: A shifting paradigm

Feature Editor's Introduction—Esophageal cancer is one of the most biologically aggressive human malignancies. After combining cytotoxic chemotherapy, radiotherapy, and major resection, less than half of treated patients are alive at 5 years. The limited efficacies of chemotherapy and radiation against esophageal cancer are showcased by state-of-the-art neoadjuvant regimens that leave residual disease in more than 70% esophageal resection specimens. That improved therapies for patients with esophageal cancer are needed is an understatement.